Personalized growth hormone pretreatment for oocyte retrieval and embryo quality in women with diminished ovarian reserve: A prospective cohort study

In patients with DOR, GH pretreatment improves treatment outcomes. Over 1 month of pretreatment can increase the oocytes retrieved but confers higher insulin resistance. Thus, when using GH for more than 4 weeks, clinicians should closely monitor HOMA-IR and perform continuous glucose monitoring; otherwise, 1-month GH pretreatment is preferred when initiating ART.